M&A Deal Summary

Juniper Pharmaceuticals Acquires Molecular Profiles

On September 12, 2013, Juniper Pharmaceuticals acquired life science company Molecular Profiles for 25M USD

Acquisition Highlights
  • This is Juniper Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Juniper Pharmaceuticals’ largest (disclosed) transaction.
  • This is Juniper Pharmaceuticals’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2013-09-12
Target Molecular Profiles
Sector Life Science
Buyer(s) Juniper Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 25M USD

Target

Molecular Profiles

Nottingham, United Kingdom
Molecular Profiles provides pharmaceutical development, clinical trial manufacturing, advanced analysis and consulting services for the pharmaceutical industry worldwide.

Search 198,123 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Juniper Pharmaceuticals

Boston, Massachusetts, United States
Category Company
Founded 1986
Sector Life Science
Employees105
Revenue 50M USD (2017)
DESCRIPTION

Juniper Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health. Juniper Pharmaceuticals was founded in 1986 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United Kingdom) 1 of 1
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal